ArticleScientific reports2025
Predicting one-year overall survival in patients with AITL using machine learning algorithms: a multicenter study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is a life-threatening hematological malignancy. For patients with poor prognosis, especially those with expected survival less than 1 year, the benefits from traditional regimens are extremely limited. Therefore, we aimed to develop an interpretable machine learning (ML)-based model to predict the 1-year overall survival (OS) of AITL patients. A total of 223 patients with AITL treated in 4 centers in China were included. Five ML algorithms were built to predict 1-year outcome based on 16 baseline characteristics. Recursive feature elimination (RFE) method was used to filter for the most important features. The ML models were interpreted and the relevance of the selected features was determined using the Shapley additive explanations (SHAP) method and the local interpretable model-agnostic explanation (LIME) algorithm. Catboost model presented to be the best predictive model (AUC = 0.8277). After RFE screening, 8 variables demonstrated the best performance (AUC = 0.8125). This study demonstrated that the Catboost model with 8 variables could effectively predict the 1-year overall survival of AITL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.